New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Stock Information for Neuronetics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Neuronetics Inc.

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference
TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics Reports Second Quarter 2025 Financial and Operating Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.